文献速递淋巴瘤

2021年弥漫性大B细胞淋巴瘤更新:风险分层与管理综述

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
PubMed 文献 · Am J Hematol · 2021-03-19

弥漫性大B细胞淋巴瘤(DLBCL)是最常见的非霍奇金淋巴瘤,具有高度异质性。R-CHOP仍为标准治疗,局限性患者近90%可获长期控制,晚期患者可达60%。综述总结了基于细胞起源和分子特征的风险分层研究,以及复发难治患者免疫治疗进展。

要点

  • R-CHOP是DLBCL一线标准方案,局限性患者长期控制率近90%,晚期可达60%。
  • 基于细胞起源和分子特征的风险分层治疗研究正在进行。
  • 复发难治患者中,过继T细胞治疗等免疫治疗显著改善结局。

核心结论

  • R-CHOP仍为DLBCL一线标准治疗,局限期与晚期患者分别有近90%和最高60%可获得长期疾病控制。
  • 肿瘤遗传学与分子特征研究已识别出对化学免疫治疗反应差的高危亚组,相关新疗法正在临床试验中评估。

研究设计与样本

  • 本文为综述,汇总近期数据并讨论初治和复发难治DLBCL治疗的持续努力。

主要发现

  • R-CHOP可使近90%的局限期患者和最高60%的晚期患者获得长期疾病控制。
  • 基于细胞起源(COO)和分子特征分类的风险适应治疗研究正在进行中。
  • 免疫治疗(主要为过继T细胞治疗)显著改善了复发难治患者的结局。

临床怎么用

  • 临床可依据细胞起源和分子特征识别高危DLBCL患者,并考虑参与风险适应治疗临床试验。
  • 复发难治DLBCL患者可考虑免疫治疗,尤其是过继T细胞治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R-CHOP remains the mainstay of therapy and can achieve long-term disease control in nearly 90% of patients presenting with limited-stage and in up to 60% of those presenting with advanced stages. Advances on the understanding of the genetic landscape and molecular features of DLBCL have identified high-risk subsets with poor outcomes to chemo-immunotherapy that are actively being studied in clinical trials. Novel therapies could potentially improve outcomes for patients with high-risk disease. Studies evaluating risk-adapted therapy based on classification by cell of origin (COO) and molecular features are ongoing. Developments in the fields of immunotherapy, mostly with adoptive T-cell therapy, have significantly improved the outcomes of patients with relapsed refractory disease. In this review, we will summarize the recent data and discuss ongoing efforts to improve DLBCL treatment in the frontline and relapsed refractory settings.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021. PMID: 33661537. doi:10.1002/ajh.26151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。